Ikena Oncology Inc
For the period ended Mar 31, 2024. Filed May 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 13, 2024
IMA$3.81-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(16,146) | $(14,219) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Depreciation | 219 | 231 |
| Net accretion of discounts on marketable securities | (393) | (530) |
| Stock-based compensation | 2,001 | 2,000 |
| Non-cash operating lease expense | 445 | 337 |
| Loss on disposal of property and equipment | 99 | — |
| Impairment of assets held for sale | 742 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (269) | 308 |
| Deposits and other assets | (102) | — |
| Accounts payable | (157) | 666 |
| Accrued expenses and other current liabilities | (3,764) | (2,919) |
| Operating lease liabilities | (993) | (345) |
| Deferred revenue | — | (5,313) |
| Other long-term liabilities | 14 | — |
| Net cash used in operating activities | (18,304) | (19,784) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | — | (152) |
| Proceeds from sale of property and equipment | 60 | — |
| Purchases of marketable securities | (62,298) | (41,726) |
| Proceeds from maturities of marketable securities | 13,500 | 31,072 |
| Net cash used in investing activities | (48,738) | (10,806) |
| Net decrease in cash, cash equivalents and restricted cash | (67,042) | (30,590) |
| Cash, cash equivalents and restricted cash, beginning of period | 121,172 | 60,791 |
| Cash, cash equivalents and restricted cash, end of period | $54,130 | $30,201 |
| Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets: | ||
| Cash and cash equivalents | $52,852 | $29,329 |
| Restricted cash included in other assets | 1,278 | 872 |
| Cash, cash equivalents and restricted cash, end of period | $54,130 | $30,201 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.